<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03483688</url>
  </required_header>
  <id_info>
    <org_study_id>CBMG-C2017007</org_study_id>
    <nct_id>NCT03483688</nct_id>
  </id_info>
  <brief_title>A PhaseⅠb Study Evaluating Safety and Efficacy of C-CAR011 Treatment in B- NHL Subjects</brief_title>
  <official_title>A Phase Ⅰb Study Evaluating Safety and Efficacy of Anti-CD19 Chimeric Antigen Receptor T-cell (C-CAR011) Treatment in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cellular Biomedicine Group Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm, single-center, non-randomized study to evaluate the safety and efficacy&#xD;
      of C-CAR011 therapy in relapsed or refractory B cell Non-Hodgkin Lymphoma (NHL).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will include the following sequential phases: Screening, Pre- Treatment (Cell&#xD;
      Product Preparation; Lymphodepleting Chemotherapy), Treatment and Follow-up&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 6, 2018</start_date>
  <completion_date type="Actual">January 10, 2020</completion_date>
  <primary_completion_date type="Actual">December 10, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AE</measure>
    <time_frame>12 weeks</time_frame>
    <description>Incidence of adverse events (AEs) and serious adverse events (SAEs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>12 months</time_frame>
    <description>The ORR will be assessed at weeks 4 ，weeks 12 ，months 6 and months 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of remission (DOR)</measure>
    <time_frame>12 months</time_frame>
    <description>The DOR will be assessed at months 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>12 months</time_frame>
    <description>The PFS will be assessed at months 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival rate（OSR）</measure>
    <time_frame>12 months</time_frame>
    <description>The OSR will be assessed at weeks 12 ，months 6 and months 12</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>B-cell Non-Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>CD19-directed CAR-T cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lymphocytes will be transduced with lentiviral vector containing CAR-CD19 gene</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CD19-directed CAR-T cells</intervention_name>
    <description>CD19-directed CAR-T cells single infusion intravenously at a target dose of 0.5-5.0 x 10^6 anti-CD19 CAR+ T cells/kg</description>
    <arm_group_label>CD19-directed CAR-T cells</arm_group_label>
    <other_name>Anti-CD19 chimeric antigen receptor T cells (C- CAR011)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Volunteered to participate in this study and signed informed consent.&#xD;
&#xD;
          -  Age 18-70 years old, male or female.&#xD;
&#xD;
          -  Relapse or refractory B cell non-Hodgkin's lymphoma ,Histologically diagnosed as&#xD;
             DLBCL,follicular lymphoma and Mantle cell lymphoma according to the NCCN. nonHodgkin's&#xD;
             lymphoma Clinical Practice Guidelines (2017 Version 1)&#xD;
&#xD;
               1. DLBCL and Follicular Lymphoma (stage Ⅲ-Ⅳ, grade Ⅲb).&#xD;
&#xD;
                    1. Progressive disease after the last standard chemotherapy regimens.&#xD;
&#xD;
                    2. Stable disease after the last standard chemotherapy regimens(at least 4&#xD;
                       cycles of first-line therapy or 2 cycles of later-line therapy).&#xD;
&#xD;
                    3. Relapse or progressive disease within 12 months after autologous stem cell&#xD;
                       transplantation (SCT).&#xD;
&#xD;
               2. Follicular lymphoma (stage Ⅲ-Ⅳ) (gradeⅠ-Ⅲa)&#xD;
&#xD;
                    1. Relapse or progressive disease within 1 year after the last standard&#xD;
                       chemotherapy regimens(At least 2 combination chemotherapy regimens).&#xD;
&#xD;
                    2. Stable disease after the last standard chemotherapy regimens(at least 2&#xD;
                       cycles of combination chemotherapy regimens).&#xD;
&#xD;
               3. Mantle cell lymphoma&#xD;
&#xD;
                    1. Relapse after 1st CR or persistent disease, and not eligible or appropriate&#xD;
                       for SCT.&#xD;
&#xD;
                    2. Relapse or progressive disease within 1 year after the last chemotherapy&#xD;
                       regimens(at least 4 cycles of first-line therapy or 2 cycles of later- line&#xD;
                       therapy).&#xD;
&#xD;
                    3. Relapse or progressive disease within 12 months after autologous SCT.&#xD;
&#xD;
          -  All subjects must have received anti-CD20 monoclonal antibody (unless tumor is&#xD;
             CD20-negative) and anthracycline-containing chemotherapy regimens according to NCCN&#xD;
             non-Hodgkin lymphoma Clinical Practice Guidelines (2017 Version 1).&#xD;
&#xD;
          -  At least one measurable lesion per revised IWG Response Criteria (the longest diameter&#xD;
             of the tumor ≥ 1.5cm).&#xD;
&#xD;
          -  Expected survival ≥ 12 weeks.&#xD;
&#xD;
          -  ECOG score 0-1.&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) ≥ 50% (detected by echocardiography).&#xD;
&#xD;
          -  No active pulmonary infections, normal pulmonary function and oxygen saturation ≥ 92%&#xD;
             on room air.&#xD;
&#xD;
          -  At least 2 weeks from receiving previous treatment (radiotherapy or chemotherapy)&#xD;
             prior to leukapheresis.&#xD;
&#xD;
          -  No contraindications of leukapheresis.&#xD;
&#xD;
          -  Female subjects in childbearing age, their serum or urine pregnancy test must be&#xD;
             negative, and must agree to take effective contraceptive measures during the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of allergy to cellular products.&#xD;
&#xD;
          -  Laboratory tests: absolute neutrophil count &lt; 1.0 × 10^9 /L, platelet count &lt; 50×10^9&#xD;
             /L, serum albumin &lt; 30 g/L,serum bilirubin &gt; 1.5 ULN, serum creatinine &gt; ULN, ALT/AST&#xD;
             &gt; 3 ULN.&#xD;
&#xD;
          -  History of CAR T cell therapy or any other genetically modified T cell therapy.&#xD;
&#xD;
          -  Relapse after allogeneic hematopoietic stem cell transplantation.&#xD;
&#xD;
          -  Active infections that require treatment (uncomplicated urinary tract infections and&#xD;
             bacterial pharyngitis are allowed), prophylactic antibiotic, antiviral and antifungal&#xD;
             treatment are permitted.&#xD;
&#xD;
          -  Hepatitis B or hepatitis C virus infection (including carriers), syphilis, as well as&#xD;
             acquired or congenital immune deficiency diseases, including but not limited to HIV&#xD;
             infection.&#xD;
&#xD;
          -  Class III or IV heart failure according to the NYHA Heart Failure Classifications.&#xD;
&#xD;
          -  QT interval prolongation ≥ 450 ms.&#xD;
&#xD;
          -  History of epilepsy or other central nervous system disorders.&#xD;
&#xD;
          -  Evidence of CNS lymphoma by head enhancement scan or magnetic resonance imaging.&#xD;
&#xD;
          -  History of other primary cancers, with the following exceptions.&#xD;
&#xD;
               1. Excisional non-melanoma (e.g. cutaneous basal cell carcinoma).&#xD;
&#xD;
               2. Cured in situ carcinoma (e.g. cervical cancer, bladder cancer, breast cancer).&#xD;
&#xD;
          -  Autoimmune diseases that require treatment, immune deficiency diseases or other&#xD;
             diseases that require immunosuppressive therapy.&#xD;
&#xD;
          -  Used of systemic steroids within two weeks (using inhaled steroids is an exception).&#xD;
&#xD;
          -  Women who are pregnant or lactating, or who have breeding intent in 6 months.&#xD;
&#xD;
          -  Participated in any other clinical trial within three months.&#xD;
&#xD;
          -  Any situation that investigators believe the risk of the subjects is increased or&#xD;
             results of the trial are disturbed.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daobin Zhou</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100010</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>March 14, 2018</study_first_submitted>
  <study_first_submitted_qc>March 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2018</study_first_posted>
  <last_update_submitted>March 3, 2020</last_update_submitted>
  <last_update_submitted_qc>March 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>B-cell Non-Hodgkin Lymphoma</keyword>
  <keyword>Refractory</keyword>
  <keyword>Relapsed</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

